These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 18509378)
1. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Guedan S; Gros A; Cascallo M; Vile R; Mercade E; Alemany R Gene Ther; 2008 Sep; 15(17):1240-5. PubMed ID: 18509378 [TBL] [Abstract][Full Text] [Related]
2. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967 [TBL] [Abstract][Full Text] [Related]
3. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897 [TBL] [Abstract][Full Text] [Related]
4. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Chen HH; Cawood R; El-Sherbini Y; Purdie L; Bazan-Peregrino M; Seymour LW; Carlisle RC Mol Ther; 2011 Jan; 19(1):67-75. PubMed ID: 20877345 [TBL] [Abstract][Full Text] [Related]
5. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer. Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593 [TBL] [Abstract][Full Text] [Related]
6. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Guedan S; Grases D; Rojas JJ; Gros A; Vilardell F; Vile R; Mercade E; Cascallo M; Alemany R Gene Ther; 2012 Nov; 19(11):1048-57. PubMed ID: 22113313 [TBL] [Abstract][Full Text] [Related]
7. Gene therapy of lung adenocarcinoma using herpes virus expressing a fusogenic membrane glycoprotein. Zhu B; Yang JR; Jiang YQ; Chen SF; Fu XP Cell Biochem Biophys; 2014 Jul; 69(3):583-7. PubMed ID: 24510538 [TBL] [Abstract][Full Text] [Related]
9. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411 [TBL] [Abstract][Full Text] [Related]
10. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439 [TBL] [Abstract][Full Text] [Related]
11. Construction of a replication-competent retroviral vector for expression of the VSV-G envelope glycoprotein for cancer gene therapy. Jin SY; Jung YT Arch Virol; 2020 May; 165(5):1089-1097. PubMed ID: 32146506 [TBL] [Abstract][Full Text] [Related]
12. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648 [TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Li H; Haviv YS; Derdeyn CA; Lam J; Coolidge C; Hunter E; Curiel DT; Blackwell JL Hum Gene Ther; 2001 Dec; 12(18):2155-65. PubMed ID: 11779400 [TBL] [Abstract][Full Text] [Related]
14. Gene therapy for acute myeloid leukemia using Sindbis vectors expressing a fusogenic membrane glycoprotein. Tan L; Xu B; Liu R; Liu H; Tan H; Huang W Cancer Biol Ther; 2010 Mar; 9(5):350-7. PubMed ID: 20061812 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of NF-kappaB in fusogenic membrane glycoprotein causing HL-60 cell death: implications for acute myeloid leukemia. Tan L; Jia H; Liu R; Wu J; Han H; Zuo Y; Yang S; Huang W Cancer Lett; 2009 Jan; 273(1):114-21. PubMed ID: 18783878 [TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effects of gene therapy with GALV membrane fusion glycoprotein in lung adenocarcinoma. Zhu B; Yang JR; Fu XP; Jiang YQ Cell Biochem Biophys; 2014 Jul; 69(3):577-82. PubMed ID: 24519667 [TBL] [Abstract][Full Text] [Related]
17. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Fielding AK; Chapel-Fernandes S; Chadwick MP; Bullough FJ; Cosset FL; Russell SJ Hum Gene Ther; 2000 Apr; 11(6):817-26. PubMed ID: 10779159 [TBL] [Abstract][Full Text] [Related]
18. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Diaz RM; Bateman A; Emiliusen L; Fielding A; Trono D; Russell SJ; Vile RG Gene Ther; 2000 Oct; 7(19):1656-63. PubMed ID: 11083474 [TBL] [Abstract][Full Text] [Related]
19. Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma. Price DL; Lin SF; Han Z; Simpson G; Coffin RS; Wong J; Li S; Fong Y; Wong RJ Arch Otolaryngol Head Neck Surg; 2010 Feb; 136(2):151-8. PubMed ID: 20157061 [TBL] [Abstract][Full Text] [Related]
20. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. Zhang J; Frolov I; Russell SJ J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]